C
CIN Terminal
Cannabis Investor News
A CanIDeal, Inc. Company
J
Live
Loading market data...
Expand
Symbol Name Exchange Last Change Volume Watch
Home › Markets › Loading…
LIEN Cannabis Finance

Chicago Atlantic BDC

NYSE · LIEN

Business development company providing senior secured loans to cannabis operators.

$9.10
+0.62%
Live Price
Price History 5 Years

Analyst Coverage

Cannabis Investor News in-house rating · cin-analyst-v1.0

Neutral Conviction 1/5
51/100 composite
Fundamentals88
Regulatory49
Market15
Editorial30
Composite · trailing 12 months

Chicago Atlantic BDC earns a Neutral rating, with a composite score in the low 50s and conviction at one out of five. The fundamentals pillar is the clear anchor, scoring in the high 80s on strong revenue growth, full gross-margin capture, and an operating margin approaching two thirds. Regulatory performance sits near the midpoint, supported by no enforcement hits but constrained by filing cadence and a neutral domestic jurisdiction posture. Market performance is the principal drag, with the mid-teens liquidity score reflecting no recorded volume in the supplied institutional pricing feeds. Editorial contribution also remains subdued, scoring around 30 as CIN newsroom coverage recorded neither newsroom nor brief activity.

Licensed fundamentals data show year-over-year revenue growth slightly above 40%, a 100% gross margin, and an operating margin just under 66%. Net income exceeds $34 million, while market capitalization stands near $225 million, placing the company below the strongest market-cap tier despite high growth and margin subscores. The stated financial condition is stable, consistent with positive net income and robust operating profitability. Primary regulatory filings show two events during the past six months, none during the latest 90-day period, and the latest filing dated in late June 2026. That cadence explains the weak regulatory cadence subscore, while the absence of enforcement hits supplies the pillar’s strongest support. Institutional pricing feeds and CIN newsroom coverage provide no offset from liquidity or visibility.

The forward catalyst rests squarely on fundamentals. Continued revenue expansion near the current pace, paired with sustained gross-margin capture and operating profitability, delivers the clearest path to a higher composite score. Stronger filing frequency would improve regulatory support, but market and editorial pillars remain too weak to drive the rating independently. A fresh primary regulatory filing that confirms continued revenue growth, high operating margins, and positive net income would reinforce the stable financial condition and raise conviction in earnings durability. The single most important signal to watch is whether the next filing preserves operating margins near two thirds while maintaining year-over-year revenue growth above 40%.

Scored: 2026-10-14Valid through: 2026-11-28Weights: Fundamentals 35% · Regulatory 25% · Market 25% · Editorial 15%
Loading CIN Rating…
Fundamentals SEC & Market Data
Loading fundamentals…
Analyst Consensus
Loading analyst data…
Valuation Multiples
Loading…
Price Statistics
Loading…
Financing Activity
Loading financing data…
Insider Transactions
Loading insider data…
Regulatory Filings
Loading regulator disclosures…
Peer Comparison
Loading peer data…
Institutional DetailIR, corporate, and filing data from CIN enrichment
Corporate DetailsCompany profile
Headquarters
600 MADISON AVE, SUITE 1800, NEW YORK, NY, 10022
Phone
(312) 625-9295
Auditor
which will increase costs associated with our periodic reporting requirements
SEC CIK
1843162
Website
Company website
Fundamentals & FinancialsRefreshed nightly from licensed fundamentals data
Market cap
$224.7M
Enterprise value
$275.1M
P/E ratio
6.5
Price to book
0.73
Price to sales
3.80
Revenue (TTM)
$59.1M
Gross profit (TTM)
$59.1M
Operating margin
65.8%
Profit margin
57.9%
Rev growth YoY
40.1%
Return on equity
11.3%
Return on assets
6.5%
EPS (TTM)
$1.50
EPS est. current year
$1.62
Wall St. target price
$11.00
Dividend per share
$1.36
Dividend yield
13.78%
Shares outstanding
22.9M
Insider ownership
0.5%
Institutional ownership
31.2%
Beta
0.27
GICS sector
Financial Services
GICS industry
Asset Management
Filings & DisclosuresPrimary sources
Annual report
Latest 10-K
Proxy statement
Latest DEF 14A
Filing portal
SEC EDGAR
See something incorrect or missing?

Help us keep coverage accurate. Submit an update for CIN editorial review.

Submit an update
Complimentary Research
Would you like a deeper analysis on this company?

Request a complimentary, fully customized institutional-quality research report — tailored to your investment thesis.

Request Complimentary Report

Bullish and Bearish Analyst Opinions for Chicago Atlantic BDC (LIEN)

Cannabis Investor News aggregates analyst coverage, price targets, insider transactions, SEC filings, and financing activity for Chicago Atlantic BDC (LIEN), a cannabis-sector equity listed on NYSE in the Cannabis Finance category. Use this profile to compare bullish and bearish opinions, monitor Form 4 insider buys and sells, and review the latest quarterly results.

Analyst average price target $11.0.

CIN editorial stance: Event-Driven Opportunity. Setup improving. Insider buying detected. (2 bullish signals, 0 bearish signals.)

Bullish and bearish analyst opinions for Chicago Atlantic BDC (LIEN)

Bullish view. Chicago Atlantic BDC is a business-development company with senior-secured lending exposure to cannabis and other niche credit segments; bulls model diversified specialty-credit spread income and NAV stability supported by first-lien positioning.

Bearish view. Bears focus on the concentration in cannabis credit specifically, sensitivity to borrower operating stress, refinancing risk in an environment of tighter credit spreads, and interest-rate-sensitive BDC valuations broadly.

Live ratings, price targets, and consensus figures for Chicago Atlantic BDC appear above this summary. Explore analyst coverage across the 326-equity cannabis universe.

Business development company providing senior secured loans to cannabis operators.

Latest price: $9.10 (+0.62%) on NYSE.

Historical Price Data

5-year weekly price history, intraday quotes, and 52-week range for LIEN are maintained by Cannabis Investor News and refreshed throughout the trading day.